1733 related articles for article (PubMed ID: 27281205)
1. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
[TBL] [Abstract][Full Text] [Related]
2. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
Sahin U; Oehm P; Derhovanessian E; Jabulowsky RA; Vormehr M; Gold M; Maurus D; Schwarck-Kokarakis D; Kuhn AN; Omokoko T; Kranz LM; Diken M; Kreiter S; Haas H; Attig S; Rae R; Cuk K; Kemmer-Brück A; Breitkreuz A; Tolliver C; Caspar J; Quinkhardt J; Hebich L; Stein M; Hohberger A; Vogler I; Liebig I; Renken S; Sikorski J; Leierer M; Müller V; Mitzel-Rink H; Miederer M; Huber C; Grabbe S; Utikal J; Pinter A; Kaufmann R; Hassel JC; Loquai C; Türeci Ö
Nature; 2020 Sep; 585(7823):107-112. PubMed ID: 32728218
[TBL] [Abstract][Full Text] [Related]
3. Review: dendritic cell immunotherapy for melanoma.
Hadzantonis M; O'Neill H
Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
[TBL] [Abstract][Full Text] [Related]
4. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids.
Paget C; Mallevaey T; Speak AO; Torres D; Fontaine J; Sheehan KC; Capron M; Ryffel B; Faveeuw C; Leite de Moraes M; Platt F; Trottein F
Immunity; 2007 Oct; 27(4):597-609. PubMed ID: 17950005
[TBL] [Abstract][Full Text] [Related]
5. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.
Skoberne M; Yewdall A; Bahjat KS; Godefroy E; Lauer P; Lemmens E; Liu W; Luckett W; Leong M; Dubensky TW; Brockstedt DG; Bhardwaj N
J Clin Invest; 2008 Dec; 118(12):3990-4001. PubMed ID: 19033668
[TBL] [Abstract][Full Text] [Related]
6. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
[TBL] [Abstract][Full Text] [Related]
7. [mRNA-transfected dendritic cells: a promising strategy in immunotherapy].
Maisnier-Patin K; Crabé S; Breton G; Dupuy FP; Yassine-Diab B; Sékaly RP
Med Sci (Paris); 2007 Mar; 23(3):279-84. PubMed ID: 17349289
[TBL] [Abstract][Full Text] [Related]
8. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
Furumoto K; Soares L; Engleman EG; Merad M
J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell vaccines for cancer immunotherapy.
Timmerman JM; Levy R
Annu Rev Med; 1999; 50():507-29. PubMed ID: 10073291
[TBL] [Abstract][Full Text] [Related]
10. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
[TBL] [Abstract][Full Text] [Related]
12. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
13. Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.
Michiels A; Breckpot K; Corthals J; Tuyaerts S; Bonehill A; Heirman C; Thielemans K; Aerts JL
Gene Ther; 2006 Jul; 13(13):1027-36. PubMed ID: 16511519
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
15. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.
Tacken PJ; de Vries IJ; Torensma R; Figdor CG
Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902
[TBL] [Abstract][Full Text] [Related]
16. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells.
Elamanchili P; Lutsiak CM; Hamdy S; Diwan M; Samuel J
J Immunother; 2007; 30(4):378-95. PubMed ID: 17457213
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma.
Metharom P; Ellem KA; Schmidt C; Wei MQ
Hum Gene Ther; 2001 Dec; 12(18):2203-13. PubMed ID: 11779404
[TBL] [Abstract][Full Text] [Related]
18. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy.
Shimizu K; Kuriyama H; Kjaergaard J; Lee W; Tanaka H; Shu S
J Immunother; 2004; 27(4):265-72. PubMed ID: 15235387
[TBL] [Abstract][Full Text] [Related]
20. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.
Goforth R; Salem AK; Zhu X; Miles S; Zhang XQ; Lee JH; Sandler AD
Cancer Immunol Immunother; 2009 Apr; 58(4):517-30. PubMed ID: 18719913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
